Literature DB >> 10670653

The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice.

J Lehmann1, K H Enssle, I Lehmann, A Emmendörfer, M L Lohmann-Matthes.   

Abstract

The immune response against Leishmania donovani infection has been investigated in one resistant mouse strain (C3H/HeJ) and three susceptible mouse strains (C57BL/6, BALB/c, and B10D2/n). In order to correlate the strain-specific course of infection with the individual T cell response phenotype, the ex vivo cytokine secretion patterns of splenic lymphocytes were assessed by ELISA (interferon-y [IFN-gamma], interleukin-4 [IL-4], IL-10) or by bioassay (IL-2). The strain-dependent differences in the course of infection correlated closely with the potency of T cells to produce IFN-gamma. C3H/HeJ mice produced high amounts of IFN-gamma before and during infection, whereas susceptible mice produced low amounts of IFN-gamma early during L. donovani infection. However, C57BL/6 mice, which recovered from the infection rapidly after the acute stage, developed marked IFN-gamma response within the first 30 days of infection. In contrast, in BALB/c and B10D2/n mice, the IFN-gamma production diminished during the acute stage, and this was associated with a delay in recovery and with subsequent switching into the chronic stage. Interestingly, CD8+ T cells contributed significantly to IFN-gamma production during this phase. In contrast to IFN-y, the levels of IL-4 in response to antigen or mitogen ex vivo were always very low. Moreover, neutralization of endogenous IL-4 in vivo by treatment with soluble murine IL-4 receptor did not result in significant decreases in the parasite burdens in spleen and liver but did cause a decrease in the serum IgE level of L. donovani-infected BALB/c mice. These results confirm that in visceral leishmaniasis a Thl-dominated immune response is protective against the L. donovani parasites and, furthermore, that the capacity to produce IFN-gamma rather than the presence of IL-4 determines the efficacy of the immune response in susceptible mice. The data show that CD8+ T cells represent an important source of IFN-gamma during L. donovani infection in susceptible mice, implying a role for this cell type in healing and development of protective immunity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10670653     DOI: 10.1089/107999000312748

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  26 in total

Review 1.  Concepts of immunostimulation to increase antiparasitic drug action.

Authors:  K Noel Masihi
Journal:  Parasitol Res       Date:  2003-01-08       Impact factor: 2.289

2.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Malnutrition alters the innate immune response and increases early visceralization following Leishmania donovani infection.

Authors:  G M Anstead; B Chandrasekar; W Zhao; J Yang; L E Perez; P C Melby
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

5.  Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate.

Authors:  Alexander B Mullen; Catherine E Lawrence; Emma McFarlane; Xiao-Quing Wei; Katharine C Carter
Journal:  Immunology       Date:  2006-07-26       Impact factor: 7.397

6.  Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination.

Authors:  Barbara Papadopoulou; Gaétan Roy; Marie Breton; Christoph Kündig; Carole Dumas; Isabelle Fillion; Ajay K Singh; Martin Olivier; Marc Ouellette
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

7.  Evaluation of TNF-α, IL-4, and IL-10 and parasite density in spleen and liver of L. (L.) chagasi naturally infected dogs.

Authors:  A DE F Michelin; S H V Perri; V M F De Lima
Journal:  Ann Trop Med Parasitol       Date:  2011-07

8.  Evaluation of parasitological and immunological parameters of Leishmania chagasi infection in BALB/c mice using different doses and routes of inoculation of parasites.

Authors:  Dulcilene M Oliveira; Mariana Amália F Costa; Miguel A Chavez-Fumagalli; Diogo G Valadares; Mariana C Duarte; Lourena E Costa; Vivian T Martins; Rosângela F Gomes; Maria N Melo; Manuel Soto; Carlos Alberto P Tavares; Eduardo Antonio F Coelho
Journal:  Parasitol Res       Date:  2011-09-14       Impact factor: 2.289

9.  Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis.

Authors:  Henry W Murray; Elaine B Brooks; Jennifer L DeVecchio; Frederick P Heinzel
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

10.  Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis.

Authors:  Saeed Ahmed; M Colmenares; L Soong; K Goldsmith-Pestana; L Munstermann; R Molina; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.